×

Cellular Biomedicine Group Announces Publication of Human Adipose-Derived Progenitor Cells to Treat Knee Osteoarthritis

SHANGHAI, China and PALO ALTO, Calif., June 5, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced the publication of the use of human adipose-derived progenitor cells (haMPCs) to treat knee osteoarthritis (KOA) in a peer-reviewed scientific journal. "We are very pleased to see this important pre-clinical data published on one of the applications of our regenerative medicine Stem Cell Platform," commented Dr. William (Wei) Cao, Chief Executive Officer of the Company. "The data bolsters our belief in the effectiveness of our lead product candidate, ReJoinTM haMPC therapy in treating KOA and promoting the regeneration of cartilage."

The publication, titled "Human Adipose-Derived Mesenchymal Progenitor Cells Engraft into Rabbit Articular Cartilage," appears online in the May edition of the International Journal of Molecular Sciences. The objective of the study was to investigate whether intra-articular injection of xenogeneic human adipose-derived mesenchymal progenitor cells (haMPCs) engrafted into rabbit articular cartilage would promote articular cartilage repair in the rabbit OA model. The haMPCs were cultured in vitro, and phenotypes and differentiation characteristics of the cells were evaluated. Assessments were carried out by macroscopic examination, hematoxylin/eosin (HE) and Safranin-O/Fast green stainings and immunohistochemistry. The data showed that haMPC treatment promoted cartilage repair. Further, we observed positive staining of human mitochondrial marker and HLA-I but not HLA-II DR on rabbit cartilage in the treated animals. The conclusion of the results is that intra-articular injection of haMPCs promotes regeneration of articular cartilage in the rabbit OA model, and supports the notion that MPCs are transplantable between HLA-incompatible individuals.

The Company is currently running a Phase IIb clinical trial of its ReJoinTM autologous human adipose-derived mesenchymal progenitor cell (haMPC) therapy for Knee Osteoarthritis (KOA), and previously released positive 24-week interim data. The Company expects to complete Phase IIb 12 month patient follow-up by the fourth quarter of 2015.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility in China, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 sarah.kelly@cellbiomedgroup.com Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 vivian.chen@grayling.com

Source:Cellular Biomedicine Group Inc.